Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company developing targeted cell therapies for autoimmune diseases, with news flow closely tied to its lead investigational CAR T cell therapy, rese-cel (resecabtagene autoleucel). The company regularly issues updates on clinical data, regulatory interactions, manufacturing progress and corporate developments that are relevant to investors and followers of autoimmune-focused biotechnology.
News about Cabaletta Bio often highlights clinical milestones within its RESET™ (REstoring SElf-Tolerance) development program. These updates include Phase 1/2 data readouts and trial expansions in indications such as myositis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, generalized myasthenia gravis and pemphigus vulgaris. Press releases have described outcomes from disease-specific cohorts, registrational cohort designs aligned with the U.S. Food and Drug Administration, and emerging data from cohorts evaluating rese-cel without preconditioning regimens.
Regulatory and manufacturing news is another key theme. Cabaletta Bio has reported on FDA designations for rese-cel, including Regenerative Medicine Advanced Therapy and Fast Track designations, as well as PRIME access from the European Medicines Agency. The company also issues announcements regarding chemistry, manufacturing and controls activities and its collaboration with Cellares to use fully automated platforms, such as the Cell Shuttle™ and Cell Q™, for clinical manufacturing and quality control testing of rese-cel.
Corporate and financial updates, including quarterly financial results, public offerings and participation in healthcare and investor conferences, are frequent components of Cabaletta Bio’s news flow. These communications provide context on the company’s cash position, operating plans and engagement with the investment community. For readers tracking CABA, the news stream offers insight into the progress of rese-cel across multiple autoimmune indications, evolving registrational strategies and the company’s preparations for potential future commercialization. Bookmarking the news feed can help users follow ongoing clinical, regulatory and corporate developments related to Cabaletta Bio and its RESET program.
Cabaletta Bio has announced a global license for a fully human CD19 binder for autoimmune disease treatment. The CABA-201 Investigational New Drug (IND) application is expected in the first half of 2023, with initial clinical data anticipated by mid-2024, subject to IND approval. This development is informed by a partnership with Dr. Georg Schett, a leader in CD19-targeting therapies. The collaboration aims to enhance understanding of immunologic responses in autoimmune conditions. CABA-201 has the potential to address diseases like systemic lupus erythematosus and rheumatoid arthritis.
Cabaletta Bio, focused on developing targeted cell therapies for autoimmune diseases, will present data from the DesCAARTes™ trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris at the 29th Annual Congress of the European Society of Gene & Cell Therapy in Edinburgh from October 11-14, 2022.
The poster, titled 'Characterization of DSG3-CAART cells prior to & following adoptive transfer in mucosal Pemphigus Vulgaris,' will be presented on October 13, 2022, by Dr. Samik Basu. More information will be available on the ESGCT website and Cabaletta’s own site post-presentation.
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology firm, announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET in New York. The event will be webcast live, and a replay will be available for 30 days on their website. Cabaletta Bio specializes in engineered T cell therapies aimed at treating autoimmune diseases, with a pipeline focusing on conditions like pemphigus vulgaris and myasthenia gravis.
Cabaletta Bio, Inc. (Nasdaq: CABA) presented new clinical data from its DesCAARTes™ trial at the EADV Congress, highlighting safety and persistence of DSG3-CAART therapy. The trial showed no dose-limiting toxicities, with one instance of grade 1 cytokine release syndrome. Importantly, while no consistent trends in antibody or disease activity reductions were noted, one patient showed significant improvement, including decreased steroid use. The company aims to prioritize a combination study using cyclophosphamide and intravenous immunoglobulin to enhance treatment efficacy.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced its participation in two investor conferences in September 2022. CEO Steven Nichtberger will engage in fireside chats at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 14, both in New York. Live webcasts will be available on the company's website, with replays accessible for 30 days.
Cabaletta Bio, Inc. (Nasdaq: CABA) announced a late-breaking presentation at the 31st EADV Congress, scheduled from September 7-10, 2022, in Milan, Italy. The presentation will focus on new clinical data from cohorts A4 and A5 of the DesCAARTes™ trial, which investigates DSG3-CAART therapy for mucosal-dominant pemphigus vulgaris. Dr. David J. Chang will present preliminary findings on September 10, 2022. Additionally, Dr. Aimee Payne will discuss CAAR T cell advancements on September 9, 2022. The trial aims to determine the maximum tolerated dose and evaluate safety and efficacy of DSG3-CAART.
Cabaletta Bio (CABA) reported its financial results for Q2 2022, revealing R&D expenses of $9.5 million, up from $7.9 million in Q2 2021. General and administrative expenses increased slightly to $3.5 million from $3.3 million. As of June 30, 2022, the company held $96.8 million in cash, down from $122.2 million at year-end 2021, but still sufficient to support operations through Q1 2024. The company is advancing its DesCAARTes™ trial and expects to present significant clinical data at the upcoming EADV Congress in September 2022.
Cabaletta Bio, Inc. (Nasdaq: CABA) presented updated clinical data from its DesCAARTes™ trial at the ASGCT Annual Meeting. The interim data, involving 12 treated subjects across four cohorts, demonstrated a favorable safety profile for DSG3-CAART with no dose-limiting toxicities. Notably, a dose-dependent increase in persistence of DSG3-CAART cells was observed. The trial aims to escalate dosages while assessing the relationship between cell persistence and clinical response in patients with mucosal-dominant pemphigus vulgaris (mPV). The company is planning additional cohorts to augment its research.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotech company, will have CEO Steven Nichtberger participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:00 a.m. ET in Miami, FL. This event will highlight the company's focus on developing targeted cell therapies for autoimmune diseases. Interested individuals can access a live webcast on the company's website, with replays available for 30 days after the event.
Cabaletta Bio (CABA) reported Q1 2022 financial results, revealing a net loss of $12.9 million, or $0.45 per share. Research and development expenses surged to $9.2 million, driven by ongoing clinical trials. The cash balance fell to $109.2 million from $122.2 million, expected to support operations until Q3 2023. Key advancements include progress in the DesCAARTes™ trial for mucosal pemphigus vulgaris and plans to initiate a first-in-human trial for MuSK-CAART in myasthenia gravis, following FDA Fast Track Designation.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
